CytomX Reports Confirmed Colorectal Cancer Responses for Varseta-M, H2 2026 Phase II Start
CytomX’s CFO reported that Varseta-M elicited confirmed responses in colorectal cancer patients within the ongoing Phase I dose-escalation study and outlined upcoming catalysts including detailed data presentations at the June ASCO conference and initiation of a Phase II dose-expansion cohort in H2 2026.
1. Varseta-M CRC Response Data
CytomX’s CFO detailed that Varseta-M has produced confirmed objective responses in its ongoing Phase I dose-escalation study for advanced colorectal cancer, demonstrating early signs of clinical activity alongside a manageable safety profile.
2. Upcoming Catalysts
Management identified key near-term milestones, including presentation of detailed Varseta-M data at the June 2026 ASCO meeting, initiation of a Phase II dose-expansion cohort in the second half of 2026, and topline efficacy and safety readouts expected in early 2027.